Opinion
Video
The Role of Guidelines on Molecular Testing in Ovarian Cancer
Author(s):
A panelist discusses how National Comprehensive Cancer Network (NCCN) guidelines have influenced molecular testing in ovarian cancer, highlighting the importance of biomarkers like BRCA genes for treatment decisions, prognostic information, and family prevention strategies.
Video content above is prompted by the following:
NCCN Guideline Updates on Molecular Testing
BRCA testing serves 3 critical functions in ovarian cancer management:
- Informs treatment decisions, particularly for PARP inhibitor therapy
- Provides prognostic information (BRCA mutations indicate better response to platinum-based chemotherapy)
- Identifies hereditary risk to enable family testing and risk-reducing surgeries
The comprehensive approach to biomarker testing has shifted from “à la carte” testing to more integrated panel testing performed at diagnosis. This ensures clinicians are prepared with complete molecular information when making treatment decisions.
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
